- Home
- LUCY vs APRE Comparison
LUCY vs APRE Comparison
Compare LUCY & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- APRE
- Stock Information
- Founded
- LUCY 2017
- APRE 2006
- Country
- LUCY United States
- APRE United States
- Employees
- LUCY N/A
- APRE N/A
- Industry
- LUCY Ophthalmic Goods
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LUCY Health Care
- APRE Health Care
- Exchange
- LUCY Nasdaq
- APRE Nasdaq
- Market Cap
- LUCY 8.9M
- APRE 10.0M
- IPO Year
- LUCY 2022
- APRE 2019
- Fundamental
- Price
- LUCY $2.08
- APRE $1.71
- Analyst Decision
- LUCY
- APRE Strong Buy
- Analyst Count
- LUCY 0
- APRE 2
- Target Price
- LUCY N/A
- APRE $15.50
- AVG Volume (30 Days)
- LUCY 5.9M
- APRE 51.7K
- Earning Date
- LUCY 08-11-2025
- APRE 08-11-2025
- Dividend Yield
- LUCY N/A
- APRE N/A
- EPS Growth
- LUCY N/A
- APRE N/A
- EPS
- LUCY N/A
- APRE N/A
- Revenue
- LUCY $1,707,470.00
- APRE $1,284,475.00
- Revenue This Year
- LUCY $367.48
- APRE N/A
- Revenue Next Year
- LUCY $166.67
- APRE N/A
- P/E Ratio
- LUCY N/A
- APRE N/A
- Revenue Growth
- LUCY 22.75
- APRE 33.27
- 52 Week Low
- LUCY $1.57
- APRE $1.41
- 52 Week High
- LUCY $13.20
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- LUCY 42.33
- APRE 52.34
- Support Level
- LUCY $1.95
- APRE $1.48
- Resistance Level
- LUCY $4.97
- APRE $1.91
- Average True Range (ATR)
- LUCY 0.35
- APRE 0.16
- MACD
- LUCY -0.09
- APRE -0.00
- Stochastic Oscillator
- LUCY 4.46
- APRE 63.14
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.